354 related articles for article (PubMed ID: 33407801)
1. Efficacy and safety of upadacitinib over 84 weeks in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE).
Kameda H; Takeuchi T; Yamaoka K; Oribe M; Kawano M; Yokoyama M; Pangan AL; Konishi Y; Meerwein S; Tanaka Y
Arthritis Res Ther; 2021 Jan; 23(1):9. PubMed ID: 33407801
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of upadacitinib in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE): a placebo-controlled phase IIb/III study.
Kameda H; Takeuchi T; Yamaoka K; Oribe M; Kawano M; Zhou Y; Othman AA; Pangan AL; Kitamura S; Meerwein S; Tanaka Y
Rheumatology (Oxford); 2020 Nov; 59(11):3303-3313. PubMed ID: 32277824
[TBL] [Abstract][Full Text] [Related]
3. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study.
Smolen JS; Pangan AL; Emery P; Rigby W; Tanaka Y; Vargas JI; Zhang Y; Damjanov N; Friedman A; Othman AA; Camp HS; Cohen S
Lancet; 2019 Jun; 393(10188):2303-2311. PubMed ID: 31130260
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial.
Genovese MC; Fleischmann R; Combe B; Hall S; Rubbert-Roth A; Zhang Y; Zhou Y; Mohamed MF; Meerwein S; Pangan AL
Lancet; 2018 Jun; 391(10139):2513-2524. PubMed ID: 29908670
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial.
Burmester GR; Kremer JM; Van den Bosch F; Kivitz A; Bessette L; Li Y; Zhou Y; Othman AA; Pangan AL; Camp HS
Lancet; 2018 Jun; 391(10139):2503-2512. PubMed ID: 29908669
[TBL] [Abstract][Full Text] [Related]
6. Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled Trial.
Fleischmann R; Pangan AL; Song IH; Mysler E; Bessette L; Peterfy C; Durez P; Ostor AJ; Li Y; Zhou Y; Othman AA; Genovese MC
Arthritis Rheumatol; 2019 Nov; 71(11):1788-1800. PubMed ID: 31287230
[TBL] [Abstract][Full Text] [Related]
7. Long-term safety and efficacy of upadacitinib versus adalimumab in patients with rheumatoid arthritis: 5-year data from the phase 3, randomised SELECT-COMPARE study.
Fleischmann R; Swierkot J; Penn SK; Durez P; Bessette L; Bu X; Khan N; Li Y; Peterfy CG; Tanaka Y; Mysler E
RMD Open; 2024 May; 10(2):. PubMed ID: 38806190
[TBL] [Abstract][Full Text] [Related]
8. Upadacitinib monotherapy versus methotrexate monotherapy in methotrexate-naïve Japanese patients with rheumatoid arthritis: a sub-analysis of the Phase 3 SELECT-EARLY study.
Takeuchi T; Rischmueller M; Blanco R; Xavier RM; Ueki Y; Atsumi T; Chen S; Friedman A; Pangan AL; Strand V; van Vollenhoven RF
Mod Rheumatol; 2021 May; 31(3):534-542. PubMed ID: 33164611
[TBL] [Abstract][Full Text] [Related]
9. The Safety Profile of Upadacitinib in Patients with Rheumatoid Arthritis in Japan.
Yamaoka K; Tanaka Y; Kameda H; Khan N; Sasaki N; Harigai M; Song Y; Zhang Y; Takeuchi T
Drug Saf; 2021 Jun; 44(6):711-722. PubMed ID: 34041702
[TBL] [Abstract][Full Text] [Related]
10. Comparative Efficacy of JAK Inhibitors for Moderate-To-Severe Rheumatoid Arthritis: A Network Meta-Analysis.
Pope J; Sawant R; Tundia N; Du EX; Qi CZ; Song Y; Tang P; Betts KA
Adv Ther; 2020 May; 37(5):2356-2372. PubMed ID: 32297280
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Upadacitinib Monotherapy in Methotrexate-Naive Patients With Moderately-to-Severely Active Rheumatoid Arthritis (SELECT-EARLY): A Multicenter, Multi-Country, Randomized, Double-Blind, Active Comparator-Controlled Trial.
van Vollenhoven R; Takeuchi T; Pangan AL; Friedman A; Mohamed MF; Chen S; Rischmueller M; Blanco R; Xavier RM; Strand V
Arthritis Rheumatol; 2020 Oct; 72(10):1607-1620. PubMed ID: 32638504
[TBL] [Abstract][Full Text] [Related]
12. Upadacitinib in patients from China, Brazil, and South Korea with rheumatoid arthritis and an inadequate response to conventional therapy.
Zeng X; Zhao D; Radominski SC; Keiserman M; Lee CK; Meerwein S; Enejosa J; Sui Y; Mohamed MF; Park W
Int J Rheum Dis; 2021 Dec; 24(12):1530-1539. PubMed ID: 34779576
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the efficacy and safety of tofacitinib and upadacitinib in patients with active rheumatoid arthritis: A Bayesian network meta-analysis of randomized controlled trials.
Song GG; Choi SJ; Lee YH
Int J Rheum Dis; 2019 Aug; 22(8):1563-1571. PubMed ID: 31211506
[TBL] [Abstract][Full Text] [Related]
14. Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response.
Fleischmann RM; Genovese MC; Enejosa JV; Mysler E; Bessette L; Peterfy C; Durez P; Ostor A; Li Y; Song IH
Ann Rheum Dis; 2019 Nov; 78(11):1454-1462. PubMed ID: 31362993
[TBL] [Abstract][Full Text] [Related]
15. Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis.
Rubbert-Roth A; Enejosa J; Pangan AL; Haraoui B; Rischmueller M; Khan N; Zhang Y; Martin N; Xavier RM
N Engl J Med; 2020 Oct; 383(16):1511-1521. PubMed ID: 33053283
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3).
Tanaka Y; Takeuchi T; Tanaka S; Kawakami A; Iwasaki M; Song YW; Chen YH; Wei JC; Lee SH; Rokuda M; Izutsu H; Ushijima S; Kaneko Y; Akazawa R; Shiomi T; Yamada E
Ann Rheum Dis; 2019 Oct; 78(10):1320-1332. PubMed ID: 31350270
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of ABT-494, a Selective JAK-1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate.
Genovese MC; Smolen JS; Weinblatt ME; Burmester GR; Meerwein S; Camp HS; Wang L; Othman AA; Khan N; Pangan AL; Jungerwirth S
Arthritis Rheumatol; 2016 Dec; 68(12):2857-2866. PubMed ID: 27390150
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial.
van der Heijde D; Song IH; Pangan AL; Deodhar A; van den Bosch F; Maksymowych WP; Kim TH; Kishimoto M; Everding A; Sui Y; Wang X; Chu AD; Sieper J
Lancet; 2019 Dec; 394(10214):2108-2117. PubMed ID: 31732180
[TBL] [Abstract][Full Text] [Related]
19. Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE study.
Fleischmann R; Mysler E; Bessette L; Peterfy CG; Durez P; Tanaka Y; Swierkot J; Khan N; Bu X; Li Y; Song IH
RMD Open; 2022 Feb; 8(1):. PubMed ID: 35121639
[TBL] [Abstract][Full Text] [Related]
20. Discontinuation of methotrexate in rheumatoid arthritis patients achieving clinical remission by treatment with upadacitinib plus methotrexate (DOPPLER study): A study protocol for an interventional, multicenter, open-label and single-arm clinical trial with clinical, ultrasound and biomarker assessments.
Shimizu T; Kawashiri SY; Sato S; Kawazoe Y; Kuroda S; Kawasaki R; Ito Y; Morimoto S; Yamamoto H; Kawakami A
Medicine (Baltimore); 2022 Jan; 101(2):e28463. PubMed ID: 35029189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
